Early data emerging from the first phase 3 trial of a malaria vaccine are raising hopes that a
licensed vaccine will soon be available for use in endemic countries, but given the relatively …

So far, the best immunization strategies to achieve high levels of protection against malaria
are based on whole parasites. Complete sterile protection can be obtained in rodent models …

The critical first step in the clinical development of a malaria vaccine, based on live-
attenuated Plasmodium falciparum sporozoites, is the guarantee of complete arrest in the …

Background Genome editing of malaria parasites is key to the generation of live attenuated
parasites used in experimental vaccination approaches. DNA repair in Plasmodium …

Despite major efforts over the past 50 years to develop a malaria vaccine, no product has
been licensed yet. Irradiated sporozoites are the benchmark for an experimental live …

Continuous stage conversion and swift changes in the antigenic repertoire in response to
acquired immunity are hallmarks of complex eukaryotic pathogens, including Plasmodium …

The worldwide burden of malaria can be substantially reduced using existing public health
interventions. However, elimination of Plasmodium will require fundamentally different …

The control and elimination of malaria caused by Plasmodium vivax is hampered by the
threat of relapsed infection resulting from the activation of dormant hepatic hypnozoites …

Historically, vaccines have been designed to mimic the immunity induced by natural
exposure to the target pathogen, but this approach has not been effective for any parasitic …

Background Antibodies have an essential role in the acquired immune response against
blood stage P. falciparum infection. Although several antigens have been identified as …